United Therapeutics advised of Watson ANDA filing for Tyvaso
US biotech firm United Therapeutics (Nasdaq: UTHR) says it has received a Paragraph IV Certification Notice Letter from Watson Laboratories, advising that it has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration requesting approval to market a generic version of Tyvaso (treprostinil) Inhalation Solution.
In the Notice Letter, Watson, which is part of Actavis and has now started trading as Allegan (NYSE: AGN) states that it intends to market a generic version of Tyvaso before the expiration of US Patent No 6,521,212, which expires in November 2018; US Patent 6,756,033, which expires in November 2018; and US Patent 8,497,393, which expires in December 2028. Tyvaso is a treatment of pulmonary arterial hypertension (PAH).
Challenge claims patents not valid
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze